Tandem Diabetes (TNDM) Q4 Sales Beat

Tandem Diabetes (NASDAQ: TNDM) reported Q4 EPS of $0.16, which may not compare to the analyst estimate of $0.21. Revenue for the quarter came in at $210 million versus the consensus estimate of $198.39 million.

GUIDANCE:

Tandem Diabetes sees FY2022 revenue of $845-860 million, versus the consensus of $827.23 million.

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• INVO Fertility (IVF) Tops Q2 EPS by 105c
• Four Tree Island Advisory calls DoubleDown $11.25 offer too low